You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CRISPR

Showing 26 - 50 of 99
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B Acute Lymphoblastic Leukemia Trial in London (PBLTT52CAR19)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • London, United Kingdom
    Great Ormond Street Hospital
Dec 15, 2021

Examining Knowledge, Attitudes, and Beliefs of Sickle Cell

Completed
  • Sickle Cell Disease
    • Bethesda, Maryland
      National Human Genome Research Institute (NHGRI)
    Feb 5, 2021

    Multiple Myeloma Trial in Worldwide (CTX120)

    Active, not recruiting
    • Multiple Myeloma
    • CTX120
    • Chicago, Illinois
    • +9 more
    Jul 14, 2022

    Multiple Myeloma, Melanoma, Synovial Sarcoma Trial in Philadelphia (biological, drug, device)

    Terminated
    • Multiple Myeloma
    • +3 more
    • NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
    • +3 more
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Oct 9, 2020

    T Cell Lymphoma Trial in Australia, Canada, United States (CTX130)

    Recruiting
    • T Cell Lymphoma
    • CTX130
    • Duarte, California
    • +9 more
    May 16, 2022

    Solid Tumor, Adult Trial in Beijing (anti-mesothelin CAR-T cells)

    Unknown status
    • Solid Tumor, Adult
    • anti-mesothelin CAR-T cells
    • Beijing, China
      Biotherapeutic Department and Hematology Department of Chinese P
    Aug 6, 2020

    Congenital Hearing Loss Trial in Shanghai (HG205)

    Not yet recruiting
    • Congenital Hearing Loss
    • HG205
    • Shanghai, China
      Eye & ENT Hospital of Fudan University
    Aug 29, 2023

    Severe Sepsis Trial in Nanjing (PCR-CRISPR/Cas12a detection)

    Unknown status
    • Severe Sepsis
    • PCR-CRISPR／Cas12a detection
    • Nanjing, Jiangsu, China
      The Affliated Drum Tower Hospital, Medical School of Nanjing Uni
    Nov 25, 2019

    B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma Trial in Worldwide (CTX110)

    Recruiting
    • B-cell Malignancy
    • +3 more
    • CTX110
    • Los Angeles, California
    • +27 more
    May 6, 2022

    Beta-Thalassemia Trial in China (BRL-101)

    Recruiting
    • Beta-Thalassemia
    • Guangzhou, Guangdong, China
    • +3 more
    Nov 7, 2022

    Tuberculosis, Pulmonary Trial in Shanghai (CRISPR-based Test)

    Unknown status
    • Tuberculosis, Pulmonary
    • CRISPR-based Test
    • Shanghai, Shanghai, China
      Huashan Hospital
    Aug 28, 2019

    Tuberculosis Trial (Quantiferon Gold, HIV serology, Respiratory secretion culture (sputum or gastric aspirate_)

    Not yet recruiting
    • Tuberculosis
    • Quantiferon Gold
    • +5 more
    • (no location specified)
    Oct 27, 2023

    Diabetes, Diabetes, Type 1, Glucose Metabolism Disorders Trial (VCTX211)

    Not yet recruiting
    • Diabetes Mellitus
    • +6 more
    • VCTX211
    • (no location specified)
    Sep 30, 2022

    Stem Cells in NF1 Tumors of the Central Nervous System

    Suspended
    • Neurofibromatosis Type 1
    • Tumors of the Central Nervous System
    • Collection of Stem Cells
    • Washington, District of Columbia
      Children's National Medical Center
    Mar 8, 2022

    Structural Chromosome Rearrangements and Brain Disorders

    Enrolling by invitation
    • Rare Diseases
    • +2 more
      • Stockholm, Sweden
        Anna Lindstrand
      Oct 2, 2023

      Acute Myeloid Leukemia Trial in United Kingdom, United States (Arm 1: NTLA-5001, Arm 2: NTLA-5001)

      Terminated
      • Acute Myeloid Leukemia
      • Arm 1: NTLA-5001
      • Arm 2: NTLA-5001
      • Los Angeles, California
      • +9 more
      Oct 13, 2022

      Novel SARS-CoV-2 Point-of-care Testing

      Recruiting
      • SARS-CoV2 Infection
      • no intervention
      • Hong Kong, Hong Kong
        Stanley Ho Centre for Emerging Infectious Diseases, The Chinese
      Aug 29, 2021

      Diabetes, Diabetes, Type 1, Glucose Metabolism Disorders Trial in Edmonton, Vancouver, Toronto (VCTX210A unit)

      Recruiting
      • Diabetes Mellitus
      • +6 more
      • VCTX210A unit
      • Edmonton, Alberta, Canada
      • +2 more
      Apr 1, 2022

      Sickle Cell Disease Trial in Birmingham, Palo Alto, Saint Louis (GPH101 Drug Product)

      Active, not recruiting
      • Sickle Cell Disease
      • GPH101 Drug Product
      • Birmingham, Alabama
      • +2 more
      Jan 5, 2023

      Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell Trial in Xi'an (XYF19

      Recruiting
      • Leukemia Lymphocytic Acute (ALL) in Relapse
      • +3 more
      • XYF19 CAR-T cell
      • +2 more
      • Xi'an, Shannxi, China
        Xijing Hospital
      Jul 27, 2019

      Solid Tumor, Adult, EGFR Overexpression Trial in Beijing (TGFßR-KO CAR-EGFR T Cells)

      Recruiting
      • Solid Tumor, Adult
      • EGFR Overexpression
      • TGFβR-KO CAR-EGFR T Cells
      • Beijing, Beijing, China
        Chinese PLA General Hospital
      Mar 25, 2022

      Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary Trial in United States (EDIT-101)

      Active, not recruiting
      • Leber Congenital Amaurosis 10
      • +6 more
      • Miami, Florida
      • +4 more
      Dec 2, 2022

      Transplacental Transmission of RSV (TTRSV)

      Recruiting
      • SARS CoV 2 Infection
      • +3 more
        • Metairie, Louisiana
        • +1 more
        Jun 29, 2022

        Survey on Precision Medicine and Digital Health

        Completed
        • Health Behavior
        • +2 more
        • Survey
        • La Jolla, California
          Scripps Green Hospital
        Dec 8, 2022

        Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for

        Recruiting
        • Nasopharyngeal Carcinoma
        • EBV antibodies test
        • EBV DNA test
        • Guangzhou, Guangdong, China
          Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
        Jul 6, 2022